

MTN-003 Study-Specific Procedures Manual

Table of Contents

Section 1. Introduction

1.1	Sources of Procedural Information.....	1-1
1.2	Investigator Responsibilities	1-1
1.3	Study Activation Process.....	1-2

Section 2. Protocol

Section 3. Documentation Requirements

3.1	Essential Documents	3-1
3.2	Participant Case History Documentation	3-2
	3.2.1 Case History Contents.....	3-2
	3.2.2 Concept of Source Data and Source Documentation	3-3
	3.2.3 Document Organization	3-5
3.3	Study Product Accountability, Chain of Custody, and Dispensing Documentation	3-6
3.4	Record Retention Requirements.....	3-8

Section 4. Participant Accrual

4.1	Study Accrual Plan and Site-Specific Accrual Targets.....	4-1
4.2	Screening and Enrollment	4-2
	4.2.1 Definition of Screening	4-2
	4.2.2 Definition of Enrollment	4-7
	4.2.3 Screening and Enrollment Timeframe.....	4-7
	4.2.4 Screening and Enrollment Logs	4-8
	4.2.5 Assignment of Participant ID Numbers	4-8
	4.2.6 Screening HIV Testing.....	4-9
	4.2.7 Eligibility Screening Scenarios	4-10
	4.2.8 Random Assignment	4-10
	4.2.8.1 Overview	4-10
	4.2.8.2 Participant-Specific Procedures.....	4-15
4.3	Product Use Instructions, First Product Use, and Adherence Counseling	4-17

Section 5. Informed Consent

5.1	Overview of Informed Consent Requirements and Procedures	5-1
5.2	Informed Consent for Screening	5-3
5.3	Informed Consent for Enrollment	5-3
	5.3.1 Informed Consent Process for Participants Who Resume Study Participation After Voluntary Withdrawal	5-3
	5.3.2 Informed Consent Support Materials	5-4
	5.3.3 Comprehension Assessment.....	5-8
5.4	Informed Consent for Specimen Storage and Possible Future Research Testing	5-10
5.5	Documenting the Informed Consent Process	5-10

Section 6. Participant Follow-up

6.1	Study Follow-up Plan and Participant Retention Targets	6-1
6.2	Types of Follow-up Visits	6-2
6.3	Follow-up Visit Scheduling.....	6-2
6.3.1	Target Visit Dates.....	6-2
6.3.2	Visit Windows.....	6-2
6.3.3	Visits Conducted Over Multiple Days: “Split Visits”	6-4
6.3.4	Missed Visits	6-5
6.4	Follow-up Visit Locations.....	6-5
6.5	Follow-up Visit Procedures.....	6-5
6.6	HIV Testing During Follow-Up	6-8
6.7	Study Product Return, Re-Supply, and Re-Issue During Follow-up.....	6-10
6.7.1	Study Product Return	6-12
6.7.2	Study Product Re-Supply	6-13
6.7.3	Study Product Re-Issue	6-17
6.8	Modified Follow-up Procedures for Participants Who Become Pregnant	6-19
6.9	Modified Follow-up Procedures for Participants Infected with Hepatitis B	6-20
6.10	Modified Follow-up Procedures for Participants Who Become Infected with HIV	6-21
6.11	Participant Transfers.....	6-24
6.12	Procedures for Participants Who Terminate Early from the Study	6-26
6.13	Resumption of Study Participation After Voluntary Withdrawal	6-26

Section 7. Visit Checklists

7.1	Use of Visit Checklists	7-1
7.2	Sequence of Procedures.....	7-2

Section 8. Participant Retention

8.1	Retention Definitions	8-1
8.2	Retention Requirements	8-2
8.3	Retention SOPs.....	8-3
8.4	Obtaining and Updating Locator Information	8-3
8.5	Retention Tips	8-4

Section 9. Study Product Considerations for Non-Pharmacy Staff

9.1	Responsibilities and Obligations with Regard to Blinding	9-1
9.2	Study Product Identification and Terminology	9-3
9.3	Study Product Regimens	9-3
9.4	Instructions for Inserting Study Gel and Taking Study Tablets	9-4
9.5	Dispensing Study Products During On-Site Visits.....	9-5
9.5.1	Dispensing from the Pharmacy Directly to Participants	9-6
9.5.2	Dispensing from the Pharmacy to Clinic Staff.....	9-6
9.5.3	Dispensing from the Pharmacy to Runners for Further Transfer to Clinic Staff	9-7
9.6	Dispensing More Than a 60-Day Supply of Study Product	9-7
9.7	Study Product Returns.....	9-9
9.8	Study Product Retrieval.....	9-9

Section 10. Clinical Considerations

10.1	Baseline Medical/Menstrual History and Ascertainment of Concomitant Medications	10-1
10.1.1	Baseline Medical/Menstrual History	10-1
10.1.2	Initial Ascertainment of Concomitant Medications	10-4
10.1.3	Pre-Existing Conditions	10-5
10.2	Interval Medical/Menstrual History and Updating of Concomitant Medications	10-5
10.2.1	Interval Medical/Menstrual History	10-5
10.2.2	Updating Concomitant Medications Information	10-6
10.3	Hepatitis B Vaccination	10-7
10.4	Physical Exams	10-7
10.4.1	Weight	10-8
10.4.2	Height	10-9
10.4.3	Blood Pressure	10-9
10.5	Pelvic Exams	10-10
10.5.1	Overview	10-10
10.5.2	Detailed Procedural Instructions	10-12
10.5.3	Documentation of Findings	10-14
10.6	Genital Bleeding Assessment	10-17
10.6.1	Genital Bleeding Assessment for Pregnant Participants	10-17
10.6.2	Participant Reports of Genital Bleeding	10-18
10.6.3	Clinician Assessment of Genital Bleeding	10-18
10.6.4	Documentation of Genital Bleeding	10-21
10.7	STI/RTI Management	10-24
10.7.1	STI/RTI Treatment	10-24
10.7.2	Screening and Enrollment Considerations	10-27
10.7.3	Adverse Event Reporting Considerations	10-28
10.8	Pap Smear Management	10-29
10.9	Urinary Tract Infections	10-30
10.10	Contraception Considerations	10-31
10.11	Pregnancy and Breastfeeding Considerations	10-32
10.12	Care and Support for Seroconverters	10-32
10.13	Calculating Creatinine Clearance Rates	10-33
10.14	Management of Laboratory Test Results	10-33
10.15	Clinical and Product Use Management	10-34

Section 11. Adverse Event Reporting and Safety Monitoring

11.1	Definitions and General Reporting Guidance	11-1
11.1.1	Adverse Event (AE)	11-1
11.1.2	Reportable Adverse Events	11-2
11.1.3	Serious Adverse Events (SAEs)	11-4
11.1.4	Expedited Adverse Events (EAEs)	11-5
11.2	Adverse Event Terminology	11-9
11.3	Adverse Event Severity	11-13
11.4	Adverse Event Relationship to Study Product Under Protocol Version 1.0	11-17
11.4.1	Adverse Event Relationship to Study Product Under Letter of Amendment #02	11-18
11.5	Adverse Event Outcomes and Follow-Up Information	11-19
11.6	Reporting Recurrent Adverse Events	11-22

11.7	Social Harms	11-23
11.8	MTN-003 Safety Monitoring, Review, and Oversight.....	11-24
11.9	Safety Distributions from DAIDS	11-25

Section 12. Counseling Considerations

12.1	HIV Counseling.....	12-1
12.2	Contraception Counseling	12-4
12.3	Study Product Adherence Counseling — Enrollment.....	12-5
	12.3.1 Product Use Instructions	12-5
	12.3.2 First Product Use.....	12-6
	12.3.3 Adherence Counseling	12-7
12.4	Study Product Adherence Counseling — Follow-up	12-9

Section 13. Laboratory Considerations

13.1	Overview and General Guidance.....	13-1
13.2	Specimen Labeling.....	13-2
13.3	Procedures for Specimens That Cannot be Evaluated.....	13-2
13.4	Use of LDMS	13-2
13.5	Urine Testing.....	13-4
	13.5.1 Specimen Collection.....	13-4
	13.5.2 Pregnancy Testing	13-4
	13.5.3 Dipstick Urinalysis	13-4
	13.5.4 Chlamydia and Gonorrhea Testing.....	13-5
13.6	Blood Testing	13-5
	13.6.1 Specimen Collection and Initial Processing	13-5
	13.6.2 HIV Testing.....	13-5
	13.6.3 Syphilis Testing.....	13-7
	13.6.4 Hepatitis B Surface Antigen and Surface Antibody	13-8
	13.6.5 Hematology Testing	13-8
	13.6.6 Serum Chemistries	13-8
	13.6.7 Plasma Archive	13-8
	13.6.8 CD4+ T Cell Count	13-9
	13.6.9 HIV RNA PCR.....	13-9
13.7	Testing of Vaginal and Cervical Specimens	13-10
	13.7.1 Vaginal pH	13-10
	13.7.2 Wet Mount for Candidiasis	13-10
	13.7.3 Rapid Test for Bacterial Vaginosis (BV)	13-11
	13.7.4 Rapid Test for Trichomoniasis.....	13-11
	13.7.5 Vaginal Gram Stain	13-12
	13.7.6 Papanicolaou (Pap) Test.....	13-13
	13.7.7 Vaginal Swabs for Biomarker Analysis	13-13
	13.7.8 Endocervical Swabs for Biomarker Analysis.....	13-13

Section 14. Data Collection

14.1	DataFax Overview.....	14-1
14.2	DataFax Form Completion.....	14-2
	14.2.1 General Guidelines.....	14-2

14.2.2	How to Mark Response Boxes	14-3
14.2.3	How to Record Numbers	14-3
14.2.4	How to Record Dates	14-4
14.2.5	How to Record Time	14-5
14.2.6	Data Corrections and Additions	14-5
14.2.7	How to Handle Missing and Unknown Data.....	14-6
14.3	MTN-003 Study-Specific Data Collection Information.....	14-7
14.3.1	Participant ID numbers (PTIDs).....	14-7
14.3.2	Study Visit Timing	14-7
14.3.3	Visit Codes and Page Numbers	14-12
14.3.4	Staff Initials/Date	14-15
14.3.5	Case Report Form Completion Schedule	14-15
14.3.6	Site Review of DataFax Forms	14-21
14.3.7	Faxing DataFax Forms	14-22
14.3.8	Non-DataFax Forms	14-22
14.4	Form Supply and Storage	14-22
14.4.1	Form and Specimen Label Supply	14-22
14.4.2	Form Storage	14-22
14.5	Completing Interviewer-administered Forms.....	14-23
14.6	Form Completion Instructions.....	14-25
14.7	Case Report Forms	14-26

Section 15. Data Communiqués

Section 16. ACASI Users Manual

Section 17. Study Reporting Plan

17.1	Purpose of Reporting Plan.....	17-1
17.2	Study Reports	17-1
17.2.1	Data Quality Control (QC) Report	17-3
17.2.2	Clinical Data Quality Control (CQC) Queries	17-3
17.2.3	Unresolved Adverse Experiences Listing	17-3
17.2.4	Specimen Monitoring Report	17-3
17.2.5	Enrollment and Retention Report.....	17-3
17.2.6	Visit Adherence and Procedure Completion Report	17-4
17.2.7	Product Adherence Report	17-4
17.2.8	Site Data Management Quality Report	17-4
17.2.9	Safety (PSRT) Reports	17-4
17.2.10	Study Monitoring Committee (SMC) Report.....	17-4
17.2.11	Data Safety Monitoring Board (DSMB) Report	17-5
17.2.12	Network Lab Assay Results Report	17-5

Section 18. Bone Mineral Density Substudy

18.1	Introduction	18-2
18.2	Protocol	18-2
18.3	Documentation Requirements	18-2
18.3.1	Essential Documents	18-2
18.3.2	Participant Case History Documentation	18-2
18.3.3	Study Product Accountability, Chain of Custody, Dispensing Documentation.....	18-3

18.3.4	Record Retention Requirements.....	18-3
18.4	Participant Accrual.....	18-3
18.4.1	Study Accrual Plan and Site-Specific Accrual Targets.....	18-3
18.4.2	Assignment of Participant ID Numbers.....	18-4
18.4.3	Screening: Definition and Procedures.....	18-4
18.4.4	Definition of Enrollment.....	18-6
18.4.5	Screening and Enrollment Timeframe.....	18-6
18.4.6	Screening and Enrollment Logs.....	18-6
18.5	Informed Consent.....	18-7
18.6	Participant Follow-up.....	18-7
18.6.1	Follow-up Visit Scheduling.....	18-7
18.6.2	Follow-up Visit Procedures.....	18-10
18.6.3	Modified Follow-up Procedures for Participants Who Temporarily Hold or Permanently Discontinue Study Product.....	18-10
18.7	Visit Checklists.....	18-10
18.8	Participant Retention.....	18-10
18.9	Study Product Considerations.....	18-10
18.10	DXA Scanning Procedures and Other Clinical Considerations.....	18-10
18.11	Adverse Event Reporting and Safety Monitoring.....	18-13
18.12	Counseling Considerations.....	18-14
18.13	Laboratory Considerations.....	18-16
18.13.1	Urine Collection and Storage.....	18-16
18.13.2	Blood Collection and Serum Storage.....	18-16
18.13.3	Guide to Logging in MTN-003B Specimens in LDMS.....	18-16
18.14	Data Collection.....	18-16
18.14.1	PTIDs.....	18-16
18.14.2	Study Visit Timing.....	18-17
18.14.3	Visit Codes.....	18-17
18.14.4	Case Report Form Completion Schedule.....	18-20
18.14.5	Form and Specimen Label Supply.....	18-20
18.14.6	Form Storage.....	18-21
18.14.7	How to Complete Interviewer-Administered Forms.....	18-21
18.14.8	Form Completion Instructions.....	18-21
18.14.9	Case Report Forms.....	18-21
18.15	Data Communiqués.....	18-21